Drug Profile
ALG APV 527
Alternative Names: 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody; ALG.APV 527Latest Information Update: 20 Feb 2023
Price :
$50
*
At a glance
- Originator Alligator Bioscience; Aptevo Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD137 antigen agonists; Trophoblastic glycoprotein 5T4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Cancer
Most Recent Events
- 13 Feb 2023 Phase-I clinical trials in Solid tumours in USA (IV)
- 09 Nov 2022 Pharmacodynamics data from a preclinical trial in solid tumours released by Alligator Bioscience & Aptevo Therapeutics
- 09 Nov 2022 Alligator and Aptevo plans to initiate a multicenter phase I trial for Solid tumours in the United States